| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Artificial intelligence entering the pathology arena in oncology: current applications and future perspectives
|
Marra, A.
|
|
|
36 |
7 |
p. 712-725
|
artikel
|
| 2 |
Circulating tumor DNA clearance as a predictive biomarker of pathologic complete response in patients with solid tumors treated with neoadjuvant immune checkpoint inhibitors: a systematic review and meta-analysis
|
Valenza, C.
|
|
|
36 |
7 |
p. 726-736
|
artikel
|
| 3 |
Comments on the study of lung cancer detection by electronic nose analysis of exhaled breath
|
Rocco, G.
|
|
|
36 |
7 |
p. 840-841
|
artikel
|
| 4 |
Decaffeinated coffee consumption and risk of total and site-specific cancer
|
Zhang, Y.
|
|
|
36 |
7 |
p. 819-831
|
artikel
|
| 5 |
Editorial Board
|
|
|
|
36 |
7 |
p. iii
|
artikel
|
| 6 |
Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma
|
Grover, P.
|
|
|
36 |
7 |
p. 807-818
|
artikel
|
| 7 |
Enrichment of CD7+CXCR3+ CAR T-cells in infusion products is associated with durable remission in relapsed or refractory diffuse large B-cell lymphoma
|
Bartolini, R.
|
|
|
36 |
7 |
p. 749-761
|
artikel
|
| 8 |
Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2− breast cancer and residual disease after neoadjuvant chemotherapy ☆
|
Loibl, S.
|
|
|
36 |
7 |
p. 832-837
|
artikel
|
| 9 |
Letter re: Efficacy and safety of neoadjuvant SHR-A1811 with or without pyrotinib in women with locally advanced or early HER2-positive breast cancer: a randomized, open-label, phase II trial
|
Zeng, X.
|
|
|
36 |
7 |
p. 838
|
artikel
|
| 10 |
Letter Re: Lung cancer detection by electronic nose analysis of exhaled breath: a multi-center prospective external validation study
|
Liu, J.
|
|
|
36 |
7 |
p. 839-840
|
artikel
|
| 11 |
Lung cancer detection by electronic nose analysis of exhaled breath: a multicentre prospective external validation study
|
Buma, A.I.G.
|
|
|
36 |
7 |
p. 786-795
|
artikel
|
| 12 |
Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial
|
Bergmann, L.
|
|
|
36 |
7 |
p. 796-806
|
artikel
|
| 13 |
Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study
|
Provenzano, L.
|
|
|
36 |
7 |
p. 762-774
|
artikel
|
| 14 |
Reply to Letter to the Editor “Lung cancer detection by electronic nose analysis of exhaled breath: a multi-center prospective external validation study” by Liu et al., G. Rocco, and Szarpak et al.
|
Buma, A.I.G.
|
|
|
36 |
7 |
p. 842-844
|
artikel
|
| 15 |
Response letter re: Efficacy and safety of neoadjuvant SHR-A1811 with or without pyrotinib in women with locally advanced or early HER2-positive breast cancer: a randomized, open-label, phase II trial
|
Li, J.J.
|
|
|
36 |
7 |
p. 839
|
artikel
|
| 16 |
Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial
|
Felip, E.
|
|
|
36 |
7 |
p. 775-785
|
artikel
|
| 17 |
Table of Contents
|
|
|
|
36 |
7 |
p. i-ii
|
artikel
|
| 18 |
The impact of the immunological context on outcomes of solid cancer patients treated with genotype-matched targeted therapies: a comprehensive review
|
Mubarak, O.
|
|
|
36 |
7 |
p. 737-748
|
artikel
|
| 19 |
The strengths and weaknesses of the final CAR-T cell-infused product are inherent to live drugs
|
Michot, J.-M.
|
|
|
36 |
7 |
p. 711
|
artikel
|
| 20 |
Validation study of electronic nose detection for lung cancer
|
Szarpak, L.
|
|
|
36 |
7 |
p. 841-842
|
artikel
|
Tijdschrift beschrijving